Colloidal Manganese Composition for Immune Enhancement Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Divalent manganese solutions used for enhancing immunity face challenges of low immune enhancement efficacy and instability due to manganese precipitation, which affects repeatability and storage stability.
Innovation Solution
The use of newly precipitated manganese and manganese colloid, specifically manganese phosphate, manganese carbonate, manganese hydroxide, or their mixtures, which are converted within a short time frame to maintain stability and enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the concentration of divalent manganese solution is increased to improve immune enhancement effect, then immune enhancement efficacy is improved, but manganese precipitation occurs which affects stability and repeatability
Solution Approach 1:
The patent changes the physical state parameter of manganese from dissolved ionic form to colloidal particle form. By controlling the formation of colloidal manganese particles with specific size distributions (0.01-10 μm), the solution achieves both high immune enhancement efficacy and stability without precipitation, resolving the contradiction between concentration and stability.
Solution Approach 2:
The patent creates a composite colloid system where manganese particles are dispersed in a stable aqueous medium with controlled particle size distribution. This composite structure allows the manganese to maintain high bioavailability and immune enhancement activity while preventing aggregation and precipitation, thus achieving both high efficacy and stability.
2Duration of action of stationary object
If divalent manganese solution is stored for extended periods, then storage stability is improved, but manganese precipitation occurs which affects repeatability
Solution Approach 1:
The patent performs preliminary stabilization by pre-forming colloidal manganese particles with controlled size distribution before storage. The particles are prepared under controlled conditions (pH, ionic strength, temperature) to ensure they remain stable during storage, preventing precipitation and maintaining repeatability throughout the storage period.
Solution Approach 2:
The patent uses colloidal particles as an intermediary form between dissolved manganese ions and solid precipitates. These colloidal particles act as stable intermediates that can be stored long-term without transforming into precipitates, thus maintaining solution stability and repeatability during extended storage periods.
3Ease of manufacture
If traditional divalent manganese solutions are used, then ease of manufacture is maintained, but immune enhancement effect is insufficient
Solution Approach 1:
The patent changes the physical state parameter of manganese from dissolved ionic form to colloidal particle form. By controlling the formation of colloidal manganese particles with specific size distributions (0.01-10 μm), the solution achieves both high immune enhancement efficacy and stability without precipitation, resolving the contradiction between concentration and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The newly precipitated manganese and manganese colloid demonstrate significantly improved immune enhancement effects compared to traditional divalent manganese solutions, with enhanced stability and repeatability.
Implementation Method 1
newly precipitated divalent manganese for enhancing immunity
Implementation Method 2
divalent manganese colloid or newly precipitated divalent manganese
Data Source
AI summary
An immune enhancement composition and a vaccine composition comprising newly precipitated manganese and/or colloid manganese, a preparation method therefor, and use thereof for immunization and/or vaccination enhancement.